EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN

N Martínez-Jañez, M Bellet Ezquerra, L M Manso Sanchez, F Henao Carrasco, A Anton Torres, S Morales, P Tolosa Ortega, V L Obadia Gil, T Sampedro, R Andrés Conejero, L Calvo-Martinez, E Galve-Calvo und 8 weitere

Breast Cancer Research and Treatment · 2024

DOI: 10.1007/s10549-024-07287-w ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Breast Cancer Research and Treatment, 2024. Verfasst von N Martínez-Jañez und 19 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Ramon y Cajal University Hospital, Hospital Ramón y Cajal, Ctra. de Colmenar Viejo km. 9,100, Madrid, 28034, Spain. Hauptthemen laut MEDLINE: Pyridines, Piperazines, Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidad Complutense de Madrid.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To evaluate the efficacy and safety of first-line therapy with palbociclib in a Spanish cohort treated after palbociclib approval.

Methods

PALBOSPAIN is an observational, retrospective, multicenter study evaluating real-world patterns and outcomes with 1 L palbociclib in men and women (any menopausal status) with advanced HR + /HER2– BC diagnosed between November 2017 and November 2019. The primary endpoint was real-world progression-free survival (rw-PFS). Secondary endpoints included overall survival (OS), the real-world response rate (rw-RR), the clinical benefit rate, palbociclib dose reduction, and safety.

Results

A total of 762 patients were included. The median rw-PFS and OS were 24 months (95% CI 21–27) and 42 months (40-not estimable [NE]) in the whole population, respectively. By cohort, the median rw-PFS and OS were as follows: 28 (95% CI 23–39) and 44 (95% CI 38-NE) months in patients with de novo metastatic disease, 13 (95% CI 11–17) and 36 months (95% CI 31–41) in patients who experienced relapse < 12 months after the end of ET, and 31 months (95% CI 26–37) and not reached (NR) in patients who experienced relapse > 12 months after the end of ET. rw-PFS and OS were longer in patients with oligometastasis and only one metastatic site and those with non-visceral disease. The most frequent hematologic toxicity was neutropenia (72%; grade ≥ 3: 52.5%), and the most common non-hematologic adverse event was asthenia (38%).

Conclusion

These findings, consistent with those from clinical trials, support use of palbociclib plus ET as 1 L for advanced BC in the real-world setting, including pre-menopausal women and men. Trial registration number NCT04874025 (PALBOSPAIN). Date of registration: 04/30/2021 retrospectively registered.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyridinesPiperazinesBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesHumansFemaleMiddle AgedAgedAdultMaleRetrospective StudiesAged, 80 and overReceptors, EstrogenReceptors, ProgesteroneProtein Kinase InhibitorsProgression-Free Survival

Stichwörter der Autor:innen

Advanced breast cancerFirst-line treatmentHR+/HER2−Overall survivalPalbociclibProgression-free survival

Substanzen

PyridinesPiperazinesErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneProtein Kinase InhibitorspalbociclibERBB2 protein, human

Autor:innen und Institutionen

  • Medical Oncology Department, Ramon y Cajal University Hospital, Hospital Ramón y Cajal, Ctra. de Colmenar Viejo km. 9,100, Madrid, 28034, Spain.
  • Oncology Department, Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, Spain.
  • Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
  • Oncology, Hospital Universitario Virgen Macarena, Seville, Spain.
  • Medical Oncology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain.
  • Medical Oncology Department, Hospital Arnau de Vilanova - Lleida, Alpicat, Spain.

Förderung

  • Universidad Complutense de Madrid

Zitieren

APA

Martínez-Jañez, N., Ezquerra, M. B., Manso Sanchez, L. M., Carrasco, F. H., Torres, A. A., Morales, S., Ortega, P. T., Gil, V. L. O., Sampedro, T., Conejero, R. A., Calvo-Martinez, L., Galve-Calvo, E., López, R., de la Pena, F. A., Lopez-Tarruella, S., de Araguiz, B. A. H. F., Ruiz, L. B., Cardenas, T. M., Chacon, J. I., & Antón, F. M. (2024). First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-024-07287-w

Vancouver

Martínez-Jañez N, Ezquerra MB, Manso Sanchez LM, Carrasco FH, Torres AA, Morales S, et al. First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN. Breast Cancer Research and Treatment. 2024. doi:10.1007/s10549-024-07287-w

BibTeX
@article{MartnezJaez2024,
  author = {Martínez-Jañez, N and Ezquerra, M Bellet and Manso Sanchez, L M and Carrasco, F Henao and Torres, A Anton and Morales, S and Ortega, P Tolosa and Gil, V L Obadia and Sampedro, T and Conejero, R Andrés and Calvo-Martinez, L and Galve-Calvo, E and López, R and de la Pena, F Ayala and Lopez-Tarruella, S and de Araguiz, B A Hernando Fernandez and Ruiz, L Boronat and Cardenas, T Martos and Chacon, J I and Antón, F Moreno},
  title = {First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN},
  journal = {Breast Cancer Research and Treatment},
  year = {2024},
  doi = {10.1007/s10549-024-07287-w}
}
Kostenlos starten →